MAP2K7 and central nervous system cancer: The RAF1 fusion activated by the RAF1 (CRAF) gene has been reported in a few melanomas and pediatric low-grade gliomas (26, 27); in some cases, MEK inhibitors have been reported to be effective against RAF1 fusions (5, 27, 28).